Illuccix

Gozetotide, the active ingredient in Illuccix, is a drug presented as an injectable solution for intravenous use. It is being evaluated in clinical studies for potential therapeutic applications, and is manufactured under EU GMP standards for distribution in European markets, though specific approved indications have not yet been established.

GNH USA supplies Illuccix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company provides regulatory support, cold‑chain logistics and customized packaging to meet global procurement requirements.

Illuccix (gozetotide) is currently under clinical investigation, and its potential therapeutic applications are being explored in several disease areas. - No publicly disclosed indications: the product is currently being studied in clinical trials.

Gozetotide, as an investigational intravenous agent, has an adverse effect profile that is still being defined.

Common Side Effects: - Infusion‑related reactions: mild fever, chills, flushing - Headache: mild to moderate intensity - Nausea: occasional and transient

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention - Cytokine release syndrome: potentially life‑threatening systemic response - Organ dysfunction: rare reports of hepatic or renal impairment

When using Illuccix, several precautionary measures should be observed to ensure patient safety. - Patient monitoring: observe for infusion reactions during and after administration - Allergy assessment: screen for known hypersensitivity to formulation components - Renal function: evaluate before dosing in patients with kidney impairment - Hepatic function: assess liver enzymes prior to therapy - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are lacking - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Potential drug interactions with Illuccix should be reviewed before therapy.

Major Interactions (Avoid): - Concomitant use with other biologics: may increase risk of immune‑mediated adverse events - Live vaccines: may reduce vaccine efficacy and increase infection risk

Moderate Interactions (Monitor Closely): - Immunosuppressants: may potentiate immunomodulatory effects, requiring dose adjustments - CYP450 substrates: potential for altered metabolism, monitor plasma levels - Anticoagulants: possible increased bleeding risk, monitor coagulation parameters